Lung cancer was considered a very rare disease in the early part of the last century, and all malignant lung tumors were considered equivalent for treatment purposes [REF].
In the early 1960s, small cell lung carcinoma (SCLC) was recognized for its unique biological behavior, including a much higher frequency of widespread metastasis at diagnosis, and a higher frequency of sensitivity to chemotherapy and radiation therapy [REF].